Info

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing products to meet unmet medical needs in neurology and psychiatry. The Company’s products include Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate extended release capsules), Antizol (fomepizole). Its clinical development pipeline consists of JZP-6 (sodium oxybate), JZP-4 (sodium channel antagonist), JZP-8 (intranasal clonazepam) and JZP-7 (ropinirole gel). The Company has an ongoing program for generating, identifying and conducting feasibility studies for new product candidates. Its JZP-7 and JZP-8 product candidates resulted from this program. Several other product candidates identified through this program are in various stages of early development, including the use of sodium oxybate for the treatment of movement disorders.(Source: 10-K)